Profiling Several Drugs in Clinical Development That Are Expected to Change the Standard of Care for Transplant Patients By 2010.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32138) has announced the addition of Prevention of Organ Transplant Rejection: Current Therapies and Novel Strategies to their offering. The practice of organ transplantation The transfer of organs such as the kidneys, heart, or liver from one body to another. The transplantation of human organs has become a common medical procedure. Typical organs transplanted are the kidneys, heart, liver, pancreas, cornea, skin, bones, and lungs. has expanded substantially since the first successful kidney transplant, more than 40 years ago. Despite improvements in the rate of acute organ rejection following transplantation, however, organ loss remains a problem. Approximately 50% of the $5 billion spent annually in the United States on organ transplants is spent on post-transplantation immunosuppressive therapy Immunosuppressive therapy Medical treatment in which the immune system is purposefully thwarted. Such treatment is necessary, for example, to prevent organ rejection in transplant cases. and/or treatment of complications following transplantation, including acute and chronic rejection. In this report, Decision Resources examine the causes of acute and chronic organ rejection and discuss the benefits and drawbacks of current treatment options. We review emerging targets for rejection therapies and discuss the strategic transition from immunosuppression immunosuppression Suppression of immunity with drugs, usually to prevent rejection of an organ transplant. Its aim is to allow the recipient to accept the organ permanently with no unpleasant side effects. to immunomodulation. Finally, the report profiles several drugs in clinical development that we expect will change the standard of care for transplant patients by 2010. Business Implications --Despite the enabling role of immunosuppressive Immunosuppressive Any agent that suppresses the immune response of an individual. Mentioned in: Antirheumatic Drugs, Graft-vs.-Host Disease, Immunosuppressant Drugs immunosuppressive 1. pertaining to or inducing immunosuppression. 2. regimens in organ transplantation, their generalized depression of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. leaves transplant patients vulnerable to infections and potential malignancies that contribute to morbidity and mortality Morbidity and Mortality can refer to:
--Numerous challenges remain in the effort to further reduce acute organ failure, and prevention of chronic organ rejection has proved even more difficult. However, the processes of acute and chronic rejection, which involve different mechanisms, have become better understood recently and are the basis of new drugs in development. --Drug combination strategies are being studied in clinical trials in hope that effective regimens can be created that will diminish or eliminate the need for long-term immunosuppressive therapy and its associated side effects Side effects Effects of a proposed project on other parts of the firm. . --The organ transplantation antirejection an·ti·re·jec·tion adj. Preventing rejection of a transplanted tissue or organ. drug segment is about to undergo a transition from the immunosuppressive drugs that have been mainstays until now to the immunomodulatory drugs currently in development. --Several new immunomodulation drugs are expected to reach the market in the near future, beginning with the launch of Novartis's FTY-720, which may be launched as early as 2006-2007, depending on trial results and regulatory reviews. Bristol-Myers Squibb's LEA-29Y and Pfizer's CP-690,550, both in Phase II clinical development, could launch closer to 2010. These three key drugs, along with ongoing clinical trials focused on the elimination of immunosuppressive drugs, are expected to permanently alter the landscape of antirejection regimens by 2010. --The Need for New Antirejection Drugs --Causes of Transplant Rejection transplant rejection Graft rejection, organ rejection, tissue rejection Immunology The constellation of host immune responses evoked when an allograft tissue is transplanted into a recipient; rejection phenomena may be minimized by optimal matching of MHC antigens --Current Therapies --New Approaches to Antirejection Drug Discovery --Emerging Drug Therapies --The Future of Antirejection Therapy Companies mentioned in this report include: --Bristol-Myers Squibb --Novartis --Pfizer For more information visit http://www.researchandmarkets.com/reports/c32138 Decision Resources |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion